Merck & Co. Stock News

Merck (MRK)'s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings exceeding expectations, the FDA's approval of Keytruda's new formulation, and an excellent upgrade from Wells Fargo, several factors contributed to this boost—let's delve into the main reasons for the r...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Citi 2025 Global Healthcare Conference.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference.

Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90.

The shortened holiday week is here, and the futures are trading higher this morning.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company's ongoing commitment to ad...

In volatile markets, Steve Cress recommends a barbell strategy: combining high-yield dividend stocks (MRK, PINE, OMF) with top AI growth stocks (MU, CLS, COMM). Seeking Alpha's quant system outperforms Wall Street by leveraging daily data, sector-relative analysis, and robust risk metrics to identify strong buys.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited “mini-tender” offer, dated November 10, 2025, to purchase up to 1,000,000 shares of Merck common stock at $65.00 per share. The offer price is approximately 24.66% below the closing price of Merck common stock on Novembe...